A new analysis of studies involving the investigational drug ocrelizumab confirms just how powerful this drug can be in treating patients with relapsing multiple sclerosis (MS), researchers say.
The analysis used NEDA (no evidence of disease activity), a composite of MRI and clinical outcomes, in the OPERA I and OPERA II clinical trials. The new analysis showed that the overall NEDA was 48% for ocrelizumab in the two studies compared with 29% for interferon β-1a in OPERA I and 25% for interferon β-1a in OPERA II.
"There was a 64% to 89% relative increase in preventing disease activity with this new therapy," said Anthony Traboulsee, MD, associate professor, Faculty of Medicine, University of British Columbia, Vancouver, and the MS Society of Canada research chair.
http://www.medscape.com/viewarticle/862648
The analysis used NEDA (no evidence of disease activity), a composite of MRI and clinical outcomes, in the OPERA I and OPERA II clinical trials. The new analysis showed that the overall NEDA was 48% for ocrelizumab in the two studies compared with 29% for interferon β-1a in OPERA I and 25% for interferon β-1a in OPERA II.
"There was a 64% to 89% relative increase in preventing disease activity with this new therapy," said Anthony Traboulsee, MD, associate professor, Faculty of Medicine, University of British Columbia, Vancouver, and the MS Society of Canada research chair.
http://www.medscape.com/viewarticle/862648
Comment